Triazolyl Tropane Derivatives As CCR5 Modulators

Details for Australian Patent Application No. 2001252482 (hide)

International Classifications

Event Publications

19 January 2006 Application Accepted

Published as AU-B-2001252482

18 May 2006 Standard Patent Sealed

17 August 2006 Application for Amendment

The nature of the amendment is as shown in the statement(s) filed 05 May 2006. Address for service in Australia - Spruson & Ferguson Level 35 St Martins Tower 31 Market Street Sydney NSW 2000

11 January 2007 Amendment Made

The nature of the amendment is as shown in the statement(s) filed 05 May 2006 and 22 June 2006

14 August 2008 Extension of Term of Standard Patents

Pfizer Inc. The earliest first regulatory approval date provided by the patentee 04 Feb 2008 For the goods Celsentri Maraviroc Applications Accepted The following application(s) for Extension of Term have been accepted under Section 74. Notice of opposition under Section 75(1) to the undermentioned application(s) for an extension of term may be filed at the Patent Office within the prescribed time.

11 September 2008 Extension of Term of Standard Patents

Pfizer Inc. The earliest first regulatory approval date provided by the patentee 04 Feb 2008 For the goods Celsentri Maraviroc Address for service in Australia: Spruson & Ferguson Level 35 St Martins Tower 31 Market Street Sydney NSW 2000

29 January 2009 Extension granted

Pfizer Inc. The earliest first regulatory approval date provided by the patentee 04 Feb 2008 For the goods Celsentri Maraviroc Extension of Term of patent pursuant to Section 77 expires on 04 Feb 2023

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.